Correlation between CD8+ T cells specific for prostate-specific antigen and level of disease in patients with prostate cancer

Eyad Elkord, Anthony W. Rowbottom, Howard Kynaston, Paul E. Williams

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Modest work has been performed to improve the sensitivity of residual disease detection or investigate the contribution that the immune system makes in controlling metastatic tumor growth, in particular, the frequency and biological actions of peptide-specific CD8+ T lymphocytes in limiting metastatic disease and/or maintaining remission. Fifty-three peripheral blood samples from 32 prostate cancer (PC) patients were investigated for the presence of circulating prostate-specific antigen (PSA)-expressing cells (CPECs) using a highly sensitive and specific assay combining immunomagnetic epithelial cell enrichment with nested RT-PCR of PSA mRNA. Using HLA-A2 tetramer complexes, frequency of CD8+ T cells specific for PSA-derived peptides was determined. Additionally, serum concentrations of PSA and testosterone were measured. CPECs were detected in 26% of peripheral blood samples from PC patients. CD8+ T cells specific for PSA-derived peptides were detected at low frequency in HLA-A2-positive PC patients. The correlation between these PSA-specific CD8+ T cells and residual prostate tumor cells and clinical measures was investigated. Our data suggest that frequency of PSA-specific CD8+ T cells is correlated to CPECs, but not to serum PSA level.

Original languageEnglish
Pages (from-to)91-98
Number of pages8
JournalClinical Immunology
Volume120
Issue number1
DOIs
Publication statusPublished - Jul 2006
Externally publishedYes

Fingerprint

Prostate-Specific Antigen
Prostatic Neoplasms
T-Lymphocytes
HLA-A2 Antigen
Peptides
Residual Neoplasm
Serum
Testosterone
Prostate
Immune System
Epithelial Cells
Polymerase Chain Reaction
Messenger RNA
Growth
Neoplasms

Keywords

  • CD8 T cells
  • Circulating PSA-expressing cells (CPECs)
  • Prostate cancer
  • Prostate-specific antigen (PSA)
  • Tetramer

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Correlation between CD8+ T cells specific for prostate-specific antigen and level of disease in patients with prostate cancer. / Elkord, Eyad; Rowbottom, Anthony W.; Kynaston, Howard; Williams, Paul E.

In: Clinical Immunology, Vol. 120, No. 1, 07.2006, p. 91-98.

Research output: Contribution to journalArticle

Elkord, Eyad ; Rowbottom, Anthony W. ; Kynaston, Howard ; Williams, Paul E. / Correlation between CD8+ T cells specific for prostate-specific antigen and level of disease in patients with prostate cancer. In: Clinical Immunology. 2006 ; Vol. 120, No. 1. pp. 91-98.
@article{08f2ba39a14345239d825430e7ff510f,
title = "Correlation between CD8+ T cells specific for prostate-specific antigen and level of disease in patients with prostate cancer",
abstract = "Modest work has been performed to improve the sensitivity of residual disease detection or investigate the contribution that the immune system makes in controlling metastatic tumor growth, in particular, the frequency and biological actions of peptide-specific CD8+ T lymphocytes in limiting metastatic disease and/or maintaining remission. Fifty-three peripheral blood samples from 32 prostate cancer (PC) patients were investigated for the presence of circulating prostate-specific antigen (PSA)-expressing cells (CPECs) using a highly sensitive and specific assay combining immunomagnetic epithelial cell enrichment with nested RT-PCR of PSA mRNA. Using HLA-A2 tetramer complexes, frequency of CD8+ T cells specific for PSA-derived peptides was determined. Additionally, serum concentrations of PSA and testosterone were measured. CPECs were detected in 26{\%} of peripheral blood samples from PC patients. CD8+ T cells specific for PSA-derived peptides were detected at low frequency in HLA-A2-positive PC patients. The correlation between these PSA-specific CD8+ T cells and residual prostate tumor cells and clinical measures was investigated. Our data suggest that frequency of PSA-specific CD8+ T cells is correlated to CPECs, but not to serum PSA level.",
keywords = "CD8 T cells, Circulating PSA-expressing cells (CPECs), Prostate cancer, Prostate-specific antigen (PSA), Tetramer",
author = "Eyad Elkord and Rowbottom, {Anthony W.} and Howard Kynaston and Williams, {Paul E.}",
year = "2006",
month = "7",
doi = "10.1016/j.clim.2005.12.008",
language = "English",
volume = "120",
pages = "91--98",
journal = "Clinical Immunology",
issn = "1521-6616",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Correlation between CD8+ T cells specific for prostate-specific antigen and level of disease in patients with prostate cancer

AU - Elkord, Eyad

AU - Rowbottom, Anthony W.

AU - Kynaston, Howard

AU - Williams, Paul E.

PY - 2006/7

Y1 - 2006/7

N2 - Modest work has been performed to improve the sensitivity of residual disease detection or investigate the contribution that the immune system makes in controlling metastatic tumor growth, in particular, the frequency and biological actions of peptide-specific CD8+ T lymphocytes in limiting metastatic disease and/or maintaining remission. Fifty-three peripheral blood samples from 32 prostate cancer (PC) patients were investigated for the presence of circulating prostate-specific antigen (PSA)-expressing cells (CPECs) using a highly sensitive and specific assay combining immunomagnetic epithelial cell enrichment with nested RT-PCR of PSA mRNA. Using HLA-A2 tetramer complexes, frequency of CD8+ T cells specific for PSA-derived peptides was determined. Additionally, serum concentrations of PSA and testosterone were measured. CPECs were detected in 26% of peripheral blood samples from PC patients. CD8+ T cells specific for PSA-derived peptides were detected at low frequency in HLA-A2-positive PC patients. The correlation between these PSA-specific CD8+ T cells and residual prostate tumor cells and clinical measures was investigated. Our data suggest that frequency of PSA-specific CD8+ T cells is correlated to CPECs, but not to serum PSA level.

AB - Modest work has been performed to improve the sensitivity of residual disease detection or investigate the contribution that the immune system makes in controlling metastatic tumor growth, in particular, the frequency and biological actions of peptide-specific CD8+ T lymphocytes in limiting metastatic disease and/or maintaining remission. Fifty-three peripheral blood samples from 32 prostate cancer (PC) patients were investigated for the presence of circulating prostate-specific antigen (PSA)-expressing cells (CPECs) using a highly sensitive and specific assay combining immunomagnetic epithelial cell enrichment with nested RT-PCR of PSA mRNA. Using HLA-A2 tetramer complexes, frequency of CD8+ T cells specific for PSA-derived peptides was determined. Additionally, serum concentrations of PSA and testosterone were measured. CPECs were detected in 26% of peripheral blood samples from PC patients. CD8+ T cells specific for PSA-derived peptides were detected at low frequency in HLA-A2-positive PC patients. The correlation between these PSA-specific CD8+ T cells and residual prostate tumor cells and clinical measures was investigated. Our data suggest that frequency of PSA-specific CD8+ T cells is correlated to CPECs, but not to serum PSA level.

KW - CD8 T cells

KW - Circulating PSA-expressing cells (CPECs)

KW - Prostate cancer

KW - Prostate-specific antigen (PSA)

KW - Tetramer

UR - http://www.scopus.com/inward/record.url?scp=33745149378&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745149378&partnerID=8YFLogxK

U2 - 10.1016/j.clim.2005.12.008

DO - 10.1016/j.clim.2005.12.008

M3 - Article

C2 - 16458609

AN - SCOPUS:33745149378

VL - 120

SP - 91

EP - 98

JO - Clinical Immunology

JF - Clinical Immunology

SN - 1521-6616

IS - 1

ER -